{"brief_title": "Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)", "brief_summary": "The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.", "condition": ["Carcinoma, Non-Small-Cell Lung"], "intervention_type": ["Drug"], "intervention_name": ["TRAIL-R1 mAb (TRM-1;HGS-ETR1)"], "criteria": "Primary Inclusion Criteria: - Relapsed or refractory histologically or cytologically confirmed Stage IIIB, IV, or recurrent NSCLC - Previously treated and failed to respond to standard therapy or progressed after standard therapy - 18 years of age or older Primary Exclusion Criteria: - Received a non-FDA approved investigational agent within the last 4 weeks. - Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies - Infection requiring antibiotics or hospitalization within the last 2 weeks - HIV, Hepatitis-B, Hepatitis-C - Pregnant or breast-feeding women - Major surgery within the last 4 weeks - History of other cancers within the past 5 years", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Carcinoma, Non-Small-Cell Lung", "Antibodies", "Antibodies, Monoclonal"], "id": "NCT00092924"}